TLR4 absence reduces neuroinflammation and inflammasome activation in Parkinson's diseases in vivo model.
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
/ pharmacology
Animals
Cytokines
/ metabolism
Disease Models, Animal
Dopaminergic Neurons
/ metabolism
Inflammasomes
/ immunology
Inflammation
/ immunology
Male
Mice
Mice, Inbred C57BL
Microglia
/ metabolism
NF-kappa B
/ metabolism
Neuroimmunomodulation
/ genetics
Neuroprotective Agents
/ pharmacology
Parkinson Disease
/ immunology
Signal Transduction
/ drug effects
Toll-Like Receptor 4
/ deficiency
Transcription Factor AP-1
/ metabolism
Tyrosine 3-Monooxygenase
/ metabolism
alpha-Synuclein
/ metabolism
AP-1
Inflammosome
MPTP
NF-κB
Parkinson’s disease
TLR4
Journal
Brain, behavior, and immunity
ISSN: 1090-2139
Titre abrégé: Brain Behav Immun
Pays: Netherlands
ID NLM: 8800478
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
19
09
2018
revised:
30
11
2018
accepted:
10
12
2018
pubmed:
15
12
2018
medline:
29
2
2020
entrez:
15
12
2018
Statut:
ppublish
Résumé
Parkinson's disease (PD) is a progressive, disabling neurodegenerative disorder. It has been shown Toll like receptor (TLR) 4-deficient mice protect against MPTP toxicity, suggesting that dopaminergic cell death is TLR4-dependent. The aim of this study was to demonstrate, in an in vivo model of PD, how TLR4 plays its important role in the pathogenesis of PD by using MPTP neurotoxin model (4 × 20 mg/kg, 2 h apart, i.p). Our experiments have demonstrated that the absence of TLR4 prevented dopamine depletion, increased tyrosine hydroxylase and dopamine transporter activities and reduced the number of α-synuclein-positive neurons. The absence of TLR4 also had an impact on inflammatory processes, modulating the transcription factors NF-κB p65 and AP-1, and reducing astrogliosis. Importantly, we demonstrated that the absence of TLR4 modulated inflammosome pathway. Moreover, it has been shown that TLR4 modulated motor and non-motor symptoms typical of PD. Our results clearly demonstrated that absence of TLR4 reduces the development of neuroinflammation associated with PD through NF-κB, AP-1 and inflammasome pathways modulation; therefore, TLR4 could be considered as an encouraging therapeutic target in neurodegenerative disorders.
Identifiants
pubmed: 30550933
pii: S0889-1591(18)30615-9
doi: 10.1016/j.bbi.2018.12.003
pii:
doi:
Substances chimiques
Cytokines
0
Inflammasomes
0
NF-kappa B
0
Neuroprotective Agents
0
Tlr4 protein, mouse
0
Toll-Like Receptor 4
0
Transcription Factor AP-1
0
alpha-Synuclein
0
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
9P21XSP91P
Tyrosine 3-Monooxygenase
EC 1.14.16.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
236-247Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.